Year in Review: Idiopathic Pulmonary Fibrosis

This publication captures a year of impactful news, insights, and updates on idiopathic pulmonary fibrosis (IPF), a serious chronic disease characterized by fibrous tissue formation in the interstitium of the lungs. IPF carries a poor prognosis as dyspnea worsens with declining lung function, and median survival is just 3 to 5 years after diagnosis. Existing antifibrotic therapies have helped some patients, but experts are hopeful that novel treatment pathways and earlier diagnosis can help more patients begin treatment with an agent that is tolerable and efficacious. These articles and interviews describe the most important happenings in the IPF landscape in 2024.

Download PDF